McKesson Surpasses Expectations: Q1 2027 Earnings and Analyst Optimism

Irving, Texas-based McKesson Corporation (MCK) is poised to test short-term earnings expectations and analyst confidence. For Q1 2027, diluted EPS is projected at $9.59, marking a 16.1% year-over-year increase from $8.26 in the prior-year quarter. The company has consistently exceeded Wall Street estimates in the past four quarters, signaling resilience in its core operations.

Earnings Projections and Growth Trajectory

■Analysts forecast full-year 2027 EPS of $44.28, up 13.2% from $39.11 in fiscal 2025.

■Long-term outlook targets $49.96 EPS for fiscal 2028, implying a 12.8% YoY rise.

■In Q4 2026, revenue fell short of estimates at $96.3 billion, but adjusted EPS of $13.71 met market expectations.

■Full-year 2026 guidance was set at $43.80-$44.60 per share.

Market Performance and Investor Sentiment

■Over the trailing 52 weeks, MCK stock gained 17.5%, trailing the S&P 500 (20.3%) and XLV healthcare ETF (20.5%).

■Among 18 analysts, 14 rate MCK as 'Strong Buy' while 4 maintain 'Hold' recommendations.

■Average analyst price target stands at $929.75, indicating a 10.5% upside from current levels.

Dr. Yaman Ege’s Analysis: McKesson’s steady growth reflects the convergence of healthcare demand and digital transformation. However, rising supply chain costs and geopolitical tensions over rare earth elements between the U.S. and China may influence investor risk perceptions. Integration with tech stocks like Nvidia underscores growing AI adoption in healthcare ecosystems.